Healthcare Finance News January 5, 2023
CMS concurs with OIG’s recommendation and says it will determine whether additional guidance would help ensure more accurate ASP calculations.
In the midst of physician concerns that Part B drug reimbursements are too low, the Department of Health and Human Services’ Office of Inspector General (OIG) is suggesting the Centers for Medicare and Medicaid Services guide drugmakers in calculating the best prices for those drugs.
In a recent report the OIG reviewed the accuracy of manufacturer-reported average sales price (ASP) data. Ensuring the accuracy of ASPs is vital, said OIG, because CMS uses these prices to directly calculate payment amounts under Medicare Part B.
Comparisons of ASPs to other benchmark prices provided little insight into potential inaccuracies, the OIG said....
Today's Sponsors
Today's Sponsor